Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
Oncotarget
; 6(6): 3918-31, 2015 Feb 28.
Article
in En
| MEDLINE
| ID: mdl-25714015
ABSTRACT
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Protoporphyrin IX (PPIX) has been used for photodynamic therapy. Mesenchymal cancer cells adapt to tumor microenvironments for growth and metastasis possibly in association with miRNA dysregulation. In view of the effect of PPIX on cancer-related genes, and its potential to inhibit tumor growth and migration/invasion, this study investigated whether PPIX enables mesenchymal liver tumor to restore dysregulated miRNAs, and if so, whether it sensitizes the cancer cells to chemotherapy. In addition, we explored new target(s) of the miRNA(s) that contribute to the anti-cancer effects. Of the ten miRNAs predicted by the 3'-UTR of HIF-1α mRNA, PPIX treatment increased miR-199a-5p, leading to the inhibition of E2F3 expression which is upregulated in mesenchymal liver tumor. miR-199a-5p levels were downregulated in HCC with E2F3 overexpression. An approach modulating epithelial-mesenchymal transition provided the expected changes in miR-199a-5p and E2F3 in vivo. PPIX prevented tumor cell growth and migration/invasion, and had a synergistic anti-cancer effect when combined with chemotherapeutics. In a xenograft model, PPIX treatment decreased overall growth and average tumor volume, which paralleled E2F3 inhibition. Overall, PPIX inhibited growth advantage and migratory ability of cancer cells and sensitized mesenchymal liver tumor cells to chemotherapeutics.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protoporphyrins
/
Antineoplastic Combined Chemotherapy Protocols
/
Photosensitizing Agents
/
Carcinoma, Hepatocellular
/
MicroRNAs
/
E2F3 Transcription Factor
/
Mesenchymal Stem Cells
/
Liver Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Oncotarget
Year:
2015
Document type:
Article